# OnCo record samarium-153-lexidronam (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/samarium-153-lexidronam/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "samarium-153-lexidronam" ;
  schema:name "Samarium-153 lexidronam"@en ;
  schema:alternateName "153Sm-EDTMP"@en, "Samarium Sm 153 lexidronam pentasodium"@en, "Quadramet" ;
  schema:description "Quadramet (samarium-153 lexidronam) is a radioactive bone-seeking injection that lodges in bone metastases and irradiates them from inside, approved in 1997 to relieve pain from prostate, breast and other cancers spread to bone. Most patients get relief within one to two weeks, but marrow suppression follows at three to five weeks, and radium-223 and PSMA radioligands have largely replaced it."@en ;
  schema:url <https://onco.cc/drugs/samarium-153-lexidronam/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Samarium_(153Sm)_lexidronam> ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/quadramet>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=samarium> ;
  onco:status "approved" ;
  onco:tag "ema-list", "supportive" ;
  onco:modality "Bone-seeking therapeutic radiopharmaceutical (beta emitter)" ;
  onco:approval "US 1997: Relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan", "EU 1998: Relief of bone pain from multiple painful osteoblastic skeletal metastases (Quadramet)" ;
  onco:related <https://onco.cc/drugs/radium-223/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/palliative-care/> ;
  onco:companies <https://onco.cc/companies/lantheus/>, <https://onco.cc/companies/curium/> ;
  onco:trials <https://onco.cc/trials/nct00551525/>, <https://onco.cc/trials/nct00450619/>, <https://onco.cc/trials/nct01886105/> .